ODAC will consider whether AstraZeneca's proposed indication in first-line mCRPC should be narrowed to patients with tumor BRCA mutations. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
